ARCHIVES

FDA Approves Gemzar For Ovarian Cancer, Contradicting ODAC Recommendation; Continues Agency Trend to Recognize Progression-Free Survival As An Endpoint.

This article is from The Cancer Letter archive.

Vol. 32 No. 28 | July 21, 2006

Download PDF Visit The Full Archive

Related Articles

NCI Advisory Group, Other Cancer Meetings

July 25, 1986

Children, Parents Differ In Decisionmaking On Cancer Treatment, Survivor Study Finds

July 29, 2005

ASCO Recommends Beginning Palliative Care Alongside Standard Therapy in Metastatic NSCLC

February 24, 2012

President’s FY 1988 Budget Request For NCI: $1.87 Billion, But It Really Isn’t What It Seems To Be

January 9, 1987

House-Senate Conferees Approve $6 Million Centers Amendment to Supplemental Appropriations Bill

June 27, 1986

Van Etten To Take Over As Director Of UC Irvine Chao Cancer Center

July 25, 2013